ITeos Therapeutics Inc

iTeos Therapeutics Inc. has faced setbacks in its clinical trials, including the termination of its Belrestotug development program and a Phase 2 lung study, leading to downgraded stock ratings and price targets.

iTeos Therapeutics Inc. is facing significant financial challenges and investor skepticism, despite its promising work in immuno-oncology therapeutics and cancer treatment.